Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Extends Bid for Orchid Cellmark for Ninth Time

NEW YORK (GenomeWeb News) – Laboratory Corporation of America has extended its cash tender offer for Orchid Cellmark for the ninth time as it continues to address questions from regulators about the proposed $85.4 million deal.

Today, LabCorp said it has extended its cash tender offer to 5 p.m. Nov. 30, after its prior extension to Nov.14 expired. In a statement, the company said that continues to cooperate with the Federal Trade Commission's request for additional information.

Also, it said that in order to allow more time to complete the deal, LabCorp, its subsidiary, OCM Acquisition, and Orchid have amended their merger agreement to extend the Extended Outside Date of the offer by an additional 30 calendar days to Dec. 14.

The depositary for the tender offer has told LabCorp that as of 5 p.m. Nov. 14, shareholders of Orchid had validly tendered and not withdrawn 26,064,267 shares of the company's stock, or about 86.8 percent of Orchid's outstanding shares. On a fully diluted basis, the figure represents about 79.7 percent of Orchid shares.

There were no shares tendered through uncovered notices of guaranteed delivery.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.